8 results on '"Hart, Olivia"'
Search Results
2. Following arrests of owners, two downtown restaurants vote to close permanently
- Author
-
Hart, Olivia HollowayKaitlyn
- Subjects
Sexual abuse ,Restaurants -- Facility closures ,News, opinion and commentary ,Sports and fitness - Abstract
Byline: Olivia HollowayKaitlyn Hart The owners of Dos Rios Cantina and The Colonial have voted to close their businesses. The decision comes after a months-long police investigation into allegations of [...]
- Published
- 2022
3. Evaluating the Cost of Pharmaceutical Purification for a Long-Duration Space Exploration Medical Foundry.
- Author
-
McNulty, Matthew J., Berliner, Aaron J., Negulescu, Patrick G., McKee, Liber, Hart, Olivia, Yates, Kevin, Arkin, Adam P., Nandi, Somen, and McDonald, Karen A.
- Subjects
SPACE exploration ,DRUG prices ,MONOCLONAL antibodies ,FOUNDRIES ,HUMAN space flight - Abstract
There are medical treatment vulnerabilities in longer-duration space missions present in the current International Space Station crew health care system with risks, arising from spaceflight-accelerated pharmaceutical degradation and resupply lag times. Bioregenerative life support systems may be a way to close this risk gap by leveraging in situ resource utilization (ISRU) to perform pharmaceutical synthesis and purification. Recent literature has begun to consider biological ISRU using microbes and plants as the basis for pharmaceutical life support technologies. However, there has not yet been a rigorous analysis of the processing and quality systems required to implement biologically produced pharmaceuticals for human medical treatment. In this work, we use the equivalent system mass (ESM) metric to evaluate pharmaceutical purification processing strategies for longer-duration space exploration missions. Monoclonal antibodies, representing a diverse therapeutic platform capable of treating multiple space-relevant disease states, were selected as the target products for this analysis. We investigate the ESM resource costs (mass, volume, power, cooling, and crew time) of an affinity-based capture step for monoclonal antibody purification as a test case within a manned Mars mission architecture. We compare six technologies (three biotic capture methods and three abiotic capture methods), optimize scheduling to minimize ESM for each technology, and perform scenario analysis to consider a range of input stream compositions and pharmaceutical demand. We also compare the base case ESM to scenarios of alternative mission configuration, equipment models, and technology reusability. Throughout the analyses, we identify key areas for development of pharmaceutical life support technology and improvement of the ESM framework for assessment of bioregenerative life support technologies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. List of Contributors
- Author
-
Williams, Carol L., Porter, Pam, Dahiya, Anju, Hubbard, William G., Bosworth, Sidney C., Pennington, Dennis, Darby, Heather M., Callahan, Christopher W., Garza, Eric L., Hanna, H. Mark, Scott, M. Sanford, Mosier, Nathan S., Hedden, Robert G., Jenkins, Robert G., Ileleji, Klein E., Martin, Chad, Jones, Don, Kirk, Dana M., Charles Gould, M., Funk, Kip, Milford, Jana, Simpkins, Travis, Duarte, Natasha, Lee Bradley, Athena, Pruszko, Rudy, McCarthy, Sean M., Melman, Jonathan H., Reffell, Omar K., Gordon-Wylie, Scott W., Laurens, Lieve M.L., Mielenz, Jonathan R., Pecha, M. Brennan, Garcia-Perez, Manuel, Altman, Richard, Tyner, Wallace E., Parsons, Bob, Cota, Matthew, Hay, F. John, Ciolkosz, Daniel, Gorton, Samuel M., Tailer, Tom, McGarvey, Ron, Snow, Heather M., Custeau, Chuck, Bellavance, Ethan, McCowen, Tracey, Csapilla, Samantha, Troester, Grant, Riggen, Adam, Brancato, Ariadne, Perruccio, Deandra, Hart, Olivia, Gutberlet, Dan, Freitas, Justin, Lisle, Isabel, Jackson, Matt, Reagan, Annie, Zohn, Brian, Sheridan, Jess, Aronow, Roz, Van Horn, Ryan, Moloznik, Alec, Beall, Ian, Cicak, Irma, Heilenbach, Kate, McGovern, Allison, Meharg, Hannah, Companion, Adam, Militi, Mike, Lindley, Amanda, MacIntyre, Claire, Beaudet, Eric, Evarts, Miranda, Barwin, Richard O., Riggs, William R., O’Shea, John C., Joslin, Thomas G., Lam, Vanessia B., and Smith, Richard P.
- Published
- 2020
- Full Text
- View/download PDF
5. A 13-Year-Old Waits for the Rapture.
- Author
-
Hart, Olivia
- Subjects
- 13-Year-Old Waits for the Rapture, A (Poem), HART, Olivia
- Abstract
The poem "A 13-Year-Old Waits for the Rapture," by Olivia Hart is presented. First Line: You are far from childhood: Last Line: sooner or later.
- Published
- 2015
6. DEAR DS.
- Author
-
Hart, Olivia and Brogan, Cathryn
- Subjects
- *
LETTERS to the editor , *DANCE , *PERFORMING arts , *PERIODICALS , *AMUSEMENTS , *ENTERTAINING - Abstract
This article presents letters to the editor relate to various articles published in different issues of the journal "Dance Spirit." Appreciation of the article "Tapping Into Your First Gig," published in the February 2004 issue of the journal; Advantages of dancing; Information on Pilobolus Dance Theatre.
- Published
- 2004
7. Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy.
- Author
-
Shishido SN, Hart O, Jeong S, Moriarty A, Heeke D, Rossi J, Bot A, and Kuhn P
- Subjects
- Humans, Receptors, Antigen, T-Cell genetics, Recurrence, Antigens, CD19, Cell- and Tissue-Based Therapy, Receptors, Chimeric Antigen genetics, Neoplasms
- Abstract
Background: Chimeric antigen receptor (CAR)-T cells are approved for use in the treatment of hematological malignancies. Axicabtagene ciloleucel (YESCARTA) and brexucabtagene autoleucel (TECARTUS) genetically modified autologous T cells expressing an anti-CD19 scFv based on the FMC63 clone have shown impressive response rates for the treatment of CD19+B cell malignancies, but there remain challenges in monitoring long-term persistence as well as the functional characterization of low-level persisting CAR-T cells in patients. Furthermore, due to CD19-negative driven relapse, having the capability to monitor patients with simultaneous detection of the B cell malignancy and persisting CAR-T cells in patient peripheral blood is important for ensuring timely treatment optionality and understanding relapse., Methods: This study demonstrates the development and technical validation of a comprehensive liquid biopsy, high-definition single cell assay (HDSCA)-HemeCAR for (1) KTE-X19 CAR-T cell identification and analysis and (2) simultaneously monitoring the CD19-epitope landscape on neoplastic B cells in cryopreserved or fresh peripheral blood. Proprietary anti-CD19 CAR reagents, healthy donor transduced CAR-T cells, and patient samples consisting of malignant B cell fractions from manufacturing were used for assay development., Results: The CAR-T assay showed an approximate limit of detection at 1 cell in 3 million with a sensitivity of 91%. Genomic analysis was additionally used to confirm the presence of the CAR transgene. This study additionally reports the successful completion of two B cell assays with multiple CD19 variants (FMC63 and LE-CD19) and a unique fourth channel biomarker (CD20 or CD22). In patient samples, we observed that CD19 isoforms were highly heterogeneous both intrapatient and interpatient., Conclusions: With the simultaneous detection of the CAR-T cells and the B cell malignancy in patient peripheral blood, the HDSCA-HemeCAR workflow may be considered for risk monitoring and patient management., Competing Interests: Competing interests: PK: founder and Chief Scientific Advisor, and received stock and receiving dividends, Epic Sciences. DH, JR and AB employed by PK. No potential conflicts of interests were disclosed by the other authors., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
8. Affinity Sedimentation and Magnetic Separation With Plant-Made Immunosorbent Nanoparticles for Therapeutic Protein Purification.
- Author
-
McNulty MJ, Schwartz A, Delzio J, Karuppanan K, Jacobson A, Hart O, Dandekar A, Giritch A, Nandi S, Gleba Y, and McDonald KA
- Abstract
The virus-based immunosorbent nanoparticle is a nascent technology being developed to serve as a simple and efficacious agent in biosensing and therapeutic antibody purification. There has been particular emphasis on the use of plant virions as immunosorbent nanoparticle chassis for their diverse morphologies and accessible, high yield manufacturing via plant cultivation. To date, studies in this area have focused on proof-of-concept immunosorbent functionality in biosensing and purification contexts. Here we consolidate a previously reported pro-vector system into a single Agrobacterium tumefaciens vector to investigate and expand the utility of virus-based immunosorbent nanoparticle technology for therapeutic protein purification. We demonstrate the use of this technology for Fc-fusion protein purification, characterize key nanomaterial properties including binding capacity, stability, reusability, and particle integrity, and present an optimized processing scheme with reduced complexity and increased purity. Furthermore, we present a coupling of virus-based immunosorbent nanoparticles with magnetic particles as a strategy to overcome limitations of the immunosorbent nanoparticle sedimentation-based affinity capture methodology. We report magnetic separation results which exceed the binding capacity reported for current industry standards by an order of magnitude., Competing Interests: AS, AG, and YG were employed by Nomad Bioscience GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 McNulty, Schwartz, Delzio, Karuppanan, Jacobson, Hart, Dandekar, Giritch, Nandi, Gleba and McDonald.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.